MedTrace Logo

Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing

NCT07462533 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-03-10

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.

Conditions

  • Skin Laxity

Interventions

DEVICE

Co2/Er:YAG

Ablative laser resurfacing treatment

DRUG

Pavise Serum

Pavise ECMR (extracellular matrix restore) serum regimen combined with laser treatment

DRUG

Sham Comparator

Vehicle serum regimen combined with laser treatment

Sponsors & Collaborators

  • Bai Biosciences

    collaborator UNKNOWN

  • Goldman, Butterwick, Fitzpatrick and Groff

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2026-07-30
Completion
2026-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07462533 on ClinicalTrials.gov